arrow
M

Maurizio Volterrani

san raffaele open university of rome
H指数:63
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial Intelligence in Cardiology: An Evidence Map Across Subspecialties, 2014–2026

心血管病学中的人工智能:跨亚专业领域的证据图谱,2014–2026

2026-09-230
OAAI
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity

奥马帕利口服剂与DPP-4抑制剂在降低老年HFpEF合并肥胖患者认知障碍风险方面的比较

2026-08-200
OAAI
Efficacy and Cost-Effective Treatment of Isometric Resistance Training for Blood Pressure Control: A Narrative Review in Healthy Individuals and People with Cardiovascular Diseases

等长抗阻训练控制血压的有效性与成本效益治疗:健康个体及心血管疾病患者叙事综述

2026-08-130
OA
Exercise training for cardiovascular prevention in patients with cancer: A scientific statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology

癌症患者心血管预防的锻炼训练:欧洲心力衰竭协会、欧洲预防心脏病学协会(ESC)和ESC心血管肿瘤学委员会的科学声明

2026-07-150
OAAI
Prevention of heart failure: A scientific statement of the Heart Failure Association, the European Association of Preventive Cardiology, and the Association of Cardiovascular Nursing & Allied Professions of the ESC, and the ESC Council on Hypertension

心力衰竭的预防:欧洲心力衰竭协会、欧洲预防心脏病学协会、心血管护理与相关职业协会以及欧洲心脏病学会高血压委员会的科学声明

2026-05-300
PRE
Hospital-to-community care pathways for patients with heart failure, an inter-society consensus document

心力衰竭患者从医院到社区的护理路径:一个跨学会共识文件

2026-05-010
PRE
Baseline characteristics of patients enrolled in the AZIMUTH trial: an e-health-integrated, smartphone app-based model of care for heart failure patients

AZIMUTH试验中入组患者的基本特征:心力衰竭患者电子健康整合、基于智能手机应用程序的护理模式

2026-05-010
PRE
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry
2025-12-010
OAAI
Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy

在心力衰竭中坚持指南指导的药物治疗。ESC心力衰竭协会 (HFA) 和ESC心血管药物治疗工作组的科学声明

2025-11-090
OAAI
Pilot Study Assessing the Hemodynamic Impact and Post-Exercise Hypotension Induced by High- Versus Low-Intensity Isometric Handgrip in Patients with Ischemic Heart Disease

初步研究评估高强度与低强度等长握力对缺血性心脏病患者血流动力学影响及运动后低血压的诱导作用

2025-10-120
OAAI
Fit but not immune from the risk: the hidden burden of dyslipidemia in elite athletes

健康但并非无风险:高脂血症在精英运动员中的隐性负担

2025-10-010
PRE
SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

SGLT2抑制剂在心力衰竭的预防和治疗中的应用:HFA和HFAI的科学声明

2025-09-190
OAAI
Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC

主动脉瓣狭窄和慢性心力衰竭的管理:欧洲心力衰竭协会(HFA)和欧洲经皮心血管介入协会(EAPCI)的ESC临床共识声明

2025-09-150
PRE
Post-Exercise Hypotension Induced by a Short Isometric Exercise Session Versus Combined Exercise in Hypertensive Patients with Ischemic Heart Disease: A Pilot Study

由短时等长运动与复合运动诱导的高血压合并缺血性心脏病患者运动后低血压:一项试点研究

2025-08-240
PRE
Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry

心力衰竭伴高血钾风险患者管理:CARE-HK in HF登记研究

2025-08-110
OAAI
Intravenous ferric carboxymaltose in heart failure with iron deficiency (FAIR-HF2 DZHK05 trial): Sex-specific outcomes

静脉用蔗糖铁在心力衰竭伴铁缺乏中的性别特异性结局(FAIR-HF2 DZHK05试验)

2025-07-310
OAAI